| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | -0.099 | 0.6 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.015 | 0.6 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.6 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | -0.082 | 0.6 |